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Abstract
Background: Fatty acid binding proteins (FABP) play an important role in carcinogenesis. Modified FABP
expression patterns were described for prostate, bladder and for renal cell carcinoma. Studies on metabolic
relationships and interactions in permanent cell lines allow a deeper insight into molecular processes. The aim of
this study is therefore a systematic overview on mRNA and protein expressions of seven FABPs in frequently used
urological cell lines.
Methods: Nine cell lines of renal carcinomas, seven of urinary bladder carcinomas, and five of prostate carcinomas
were investigated. Quantitative RT-qPCR and western blotting were used to determine different FABPs. In addition,
46 paired cancerous and noncancerous tissue samples from nephrectomy specimen with renal cell carcinomas
were investigated regarding the ileum FABP mRNA expression level and associated with survival outcome.
Results: General characteristics of all urological carcinoma cell lines were the expression of E-and IL-FABP on
mRNA and protein level, while the expressions differed between the cell lines. The protein expression was not
always congruent with the mRNA expression. Renal cell carcinoma cell lines showed expressions of L-, H- and B-
FABP mRNA in addition to the general FABP expression in five out of the eight investigated cell lines. In bladder
cancer cell lines, we additionally found the expression of A-FABP mRNA in six cell lines, while H-FABP was present
only in three cell lines. In prostate cancer cell lines, a strong reduction of A- and E- FABP mRNA was observed. The
expression of B-FABP mRNA and protein was observed only in the 22 RV-1 cells. IL-FABP mRNA was over-expressed
in renal tumour tissue. The IL-FABP ratio was identified as an independent indicator of survival outcome.
Conclusions: Distinctly different FABP expression patterns were observed not only between the cell lines derived
from the three cancer types, but also between the cell lines from the same cancer. The FABP patterns in the cell
lines do not always reflect the real situation in the tumours. These facts have to be considered in functional studies
concerning the different FABPs.
Background
Fatty acid binding proteins (FABPs) represent a family
of cytosolic proteins containing 9 different types. The
designations for the FABPs were derived from the tissue
from which they had originally been isolated and
include: (1) liver (L-FABP); (2) intestine (I-FABP); (3)
heart (H-FABP); (4) adipocyte (A-FABP); (5) epidermis
(E-FABP); (6) ileal (IL-FABP); (7) brain (B-FABP); (8)
myelin (M-FABP) and (9) testis (T-FABP). The FABPs
bind different fatty acids and take on the transport to
cellular compartments. Thus, FABPs are involved in
lipid metabolism and regulation of gene expression [1].
Recently, it has been shown that FABPs play an impor-
tant role in carcinogenesis. Respective studies in solid
tumours are summarised in table 1. Regarding urological
tumours, modified FABP expression patterns were
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any medium, provided the original work is properly cited.described for prostate [2] and urinary bladder cancer [3]
as well as for renal cell carcinoma [4]. Hammamieh et
al. [2] proved the influence of the FABPs on prolifera-
tion and apoptosis in prostate cancer. The loss of A-
FABP expression in bladder carcinomas occurs mainly
in invasive urothelial carcinomas [3] suggesting that
FABPs could be used as tumour markers. In renal cell
carcinomas, L- and H-FABP were decreased and B-
FABP was up-regulated [4,5].
For studying metabolic relationship and interaction it
is necessary to work with permanent cell lines derived
from human tumours that allow a deeper insight into
molecular processes. It is therefore the aim of this study
to give a systematic overview on the mRNA and protein
expression of seven FABPs in frequently used urological
cell lines since information about FABPs in cell lines
[2,6] is scarce and incomplete. In the present study,
nine cell lines of renal carcinomas, seven of urinary
bladder carcinomas and five of prostate carcinomas
were included and present the essential object of our
investigations. IL-FABP expression on transcript level in
renal cell carcinoma tissues and its prognostic value is
additionally given as preliminary study for the use of
FABPs in clinical research. We decided to study renal
cell carcinoma as example for clinical specimens, since
our group have already investigated in previous studies
[4] the expression of the two FABP-types B-FABP and
L-FABP in renal cell carcinomas.
Methods
Cell culture
Cell lines originating from renal cell carcinoma, bladder
and prostate cancer representing the three most fre-
quent urologic carcinomas were included in the study
(Table 2). Cells purchased from American Type Culture
Collection (Manassas, VA USA) and from German Col-
lection of Microorganism and Cell Culture (Braunsch-
weig, Germany) were cultured as described in the
manufacturer’s instructions. The LNCaP and SW-839
cells were cultured in Primaria flasks (Becton, Dickinson
and Company, Heidelberg, Germany) and all the other
cells in standard usual flasks (Becton, Dickinson and
Company) maintained in a humid chamber at 37°C and
5% CO2. All cell lines except Caki-1, Caki-2, SW 839
were maintained in RPMI 1640 medium. Caki-1, Caki-2
and SW 839, ACHN and HK-2 were maintained in
McCoy’s 5A medium, the cell line ACHN in MEM
medium and the HK-2 cells in K-SFM medium. All tis-
sue culture media were obtained from Invitrogen GmbH
(Karlsruhe, Germany) and fetal calf serum from PAA
Laboratories GmbH (Pasching, Austria). The media
were supplemented with antibiotics (1 × penicillin/strep-
tomycin: 100 U/ml and 100 μg/ml, PAA Laboratories).
All cells were harvested under microscopic control with
a solution of 0.5 g/l trypsin plus 0.2 g/l EDTA (Invitro-
gen GmbH) solved in PBS and frequently washed and
counted in Dulbecco’s PBS from PAA Laboratories.
Tumour material and clinico-pathological data of patients
Forty-six matched (malignant and non-malignant) kid-
ney specimens from primary tumours were used for
total RNA isolation. The samples were derived from
patients with renal cell carcinomas (RCC) undergoing
radical tumour nephrectomy at the Department of Urol-
ogy, Charité - Universitätsmedizin Berlin, Germany
between 2003 and 2005. Staging met the UICC 2002 cri-
teria. Histological classification was performed according
to the WHO criteria; tumour grading was accomplished
according to Fuhrman. The clinico-pathological para-
meters in all RCC were summarised in table 3. The end-
point of the survival analyses was the cancer-related
survival measured from the date of the radical nephrect-
omy to the time of the last follow-up or death. This
study has been approved by the Charité University
Ethics Committee.
RNA isolation from cells and tissue samples
The total RNA from cells and tissue material were iso-
lated using the RNeasy mini Kit from Qiagen (Qiagen
GmbH, Hilden, Germany). The cell number was
adjusted between 2 and 6 × 10
6 cells. All preparation
steps were performed according to the supplier’sp r o t o -
c o l .T h es a m p l ep a i r sf r o mt h es a m ek i d n e yw e r ec o l -
lected immediately after surgery in RNAlater
®
Stabilization Reagent (Qiagen, Hilden, Germany), stored
o v e r n i g h ta t4 ° Ca n da t- 8 0 ° Ca f t e r w a r d s .T h eR N A
Table 1 Investigated FABP subtypes in solid carcinomas
FABP subtypes Solid carcinomas
liver FABP (1) colon [15], breast [16], kidney [4], liver [17], prostate [2], stomach [18],
intestine FABP (2) colon [19], breast [16]
heart FABP (3) kidney [5], stomach [20]
adipocyte FABP (4) bladder [3], breast [16,21], prostate [2]
epidermal FABP (5) bladder [14], breast [16], oral [22], pancreas [23], prostate [2]
ileum FABP (6) colon [24]
brain FABP (7) glioblastom [25,26], kidney [4], melanoma [27,28]
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Page 2 of 10isolation was performed as formerly described by our
g r o u p[ 4 ]a n dr e s u l t e di nR N As a m p l e sw i t ha na b s o r -
bance of 260/280 nm ratio in the range from 1.96 to
2.08 and RNA integrity values of 9.7 ± 0.8 (mean ± SD)
for renal, of 9.9 ± 0.22 for prostate and of 10.0 ± 0.08
for bladder cell lines as well as of 8.4 ± 1.02 for tissue
samples.
Real-Time PCR
One μg RNA of the various urological cell lines and of
the kidney tissues respectively, was reverse transcribed
using the Transcriptor First Strand cDNA Synthesis Kit
(Roche Applied Science, Mannheim, Germany) by ran-
dom hexamer priming method according to the manu-
facturer’s recommendations. The detailed procedure was
previously described [4]. All used primers and probes
were summarised in table 4.
The previously characterised conditions [4] were used
for all materials and for all FABP types except A-FABP,
for which an annealing temperature of 58°C for 20 s
was preferred. For relative quantification of FABP
mRNA expression, we also determined the two genes
TATA box-binding protein (TBP) and peptidylproline
isomerase A (PPIA) verified in a previous study as most
suitable reference genes for gene profiling studies in
renal cell carcinoma tissue [7]. Standard curves were
generated for all gene-specific PCRs with cDNA samples
from cell lines or tissues to calculate gene expression
and PCR efficiencies that were between 1.85 and 2.01.
The specificity of PCR was checked by the length of
PCR products using agarose gel electrophoresis (Figure
1). All samples were measured in duplicates. The intra-
serial run precision (n = 9) of the PCR measurements,
measured by the determination of IL-FABP amounted
to a variation coefficient of 6.62% at a mean concentra-
tion of 2.66 × 10
-2 (Cq-value of 26.09).
Protein extraction and western blot analysis
Suspensions of 2 - 3 × 10
7 cells were washed two times
in PBS and then sedimented by 300 × g centrifugation
for 10 min. Cell lysates were prepared according to the
method of Zigrino et al. [8]. Protein extraction of paired
tissue samples (carcinoma/normal) from six nephrect-
omy specimens was carried out as described by
Fritzsche et al. [9]. All protein extracts were run under
reducing conditions in a 15% SDS-polyacrylamide gel.
Western blot analysis was carried out using the standard
protocol for protein transfer onto PVDF membrane
(Millipore Corp, Bedford, MA, USA) according to Tow-
bin et al. [10]. Western blotting was performed with
FABP type specific antibodies as summarised in table 5.
Table 2 Examined cell lines of urological carcinomas in this study
Renal cell carcinoma Prostate carcinoma Urinary bladder carcinoma
Cell line Origin Cell line Origin Cell line Origin
786-0 Primary adenocarcinoma BPH-1 Benign hyperplasia HCV-29 Normal bladder irradiated
A 498 Primary tumour DU-145 Metastasis of brain HT-1376 Primary transitional cell carcinoma G3
A 704 Primary adenocarcinoma LNCaP Metastasis of lymph node J-82 Primary transitional cell Carcinoma
ACHN Primary adenocarcinoma PC-3 Metastasis of bone marrow RT-4 Primary transitional cell carcinoma T2,G1
Caki-1 Clear cell carcinoma Metastasis of skin 22 RV-1 Primary tumour RT-112 Primary transitional Cell carcinoma G2
Caki-2 Primary clear cell carcinoma SCaBER Primary squamous Cell carcinoma
HK-2 Normal tissue proximal tubule UM-UC-3 Primary transitional cell carcinoma
SN-12 Primary tumour
SW 839 Primary tumour
Table 3 Clinico-pathological characteristics of the study
cohort of patients with renal cell carcinomas
Total Clear cell
RCC
papillary
RCC
Other**
RCC
All cases 46 36 2 8
Age, years* 40 - 78
Median* 61.0
Sex male 35
female 11
Grading G1 3 3
G2 30 27 2 1
G3 11 6 5
G4 2 2
pT State pT1a 6 6
pT1b 8 6 2
pT2 2 2
pT3a 11 8 3
pT3b 15 11 2 2
pT3c 2 2
pT4 2 1 1
Metastasis M0 27 24 1 2
M1 19 12 1 6
Lymph nodes N0 14 14
N1 9 4 2 3
NX 23 18 5
* Values are given as range and median
** This group involves six sarcomatoide, one mixed form (clear cell/papillary)
and one Ductus Bellini carcinoma
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Gene Accession number Primer Sequences (5’...3’) Product size[bp] UPL probe*
L-FABP1 NM_001443 Forward ttctccggcaagtaccaact 93 72
Reverse cttccccttctggatgagc
I-FABP2 NM_000134 Forward acaacctagcagacggaactg 78 1
Reverse tccgtttgaattttccaataagtt
H-FABP3 NM_004102 Forward ctgggcacctggaagcta 77 56
Reverse ctggtagcaaaacccacacc
A-FABP4 NM_001442 Forward cctttaaaaatactgagatttccttca 105 72
Reverse ggacacccccatctaaggtt
E-FABP5 NM_001444 Forward gcagacccctctctgcac 138 56
Reverse tcgcaaagctattcccactc
IL-FABP6 NM_001445 Forward ctcagagatcgtgggtgaca 68 22
Reverse tcacgcgctcataggtca
B-FABP7 NM_001446 Forward ctcagcacattcaagaacacg 69 33
Reverse ccatccaggctaacaacagac
TBP NM_003194 Forward ttcggagagttctgggattgta 227
Reverse tggactgttcttcactcttggc
Probe:
F-ccgtggttcgtggctctcttatcctcaT-P
PPIA NM_021130 Forward Hs_PPIA_I_SG 121
Reverse QuantiTect Primer Assay
Qiagen
(Cat. No. QT00052311)
* UPL probes from Universal ProbeLibrary; Roche
1  2  3  4  5   6  7  8
1. L-FABP (93 bp)
2. I-FABP  (78 bp)
3. H-FABP (77 bp)
4. DNA Molecular Weight
Marker VIII (Roche)
5. A-FABP (105 bp)
6. E-FABP (138 bp)
7. IL-FABP (68 bp)
8. B-FABP (104 bp)
1114
900
692
501
489
404
320
242
190
147
124
110
67
19/37
(bp)
{
Primer
Figure 1 A submarine agarose gel electrophoresis for PCR product control. The PCR amplificates run in 3% (w/v) agarose, small DNA low
melt (Biozym, Oldendorf, Germany) in TBE buffer pH 8 and ethidium bromide (0.5 μg/ml).
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reaction was visualized by ECL Advance™ Western
Blotting Detection Kit (GE Healthcare UK Limited, Lit-
tle Chalfont Buckinghamshire, UK). Intensity of the
detected signals by Western blot was quantified with
Fluor-S MultiImager (Bio-Rad Laboratories, Hercules,
USA).
Statistical analysis
Statistical analysis was performed with SPSS, version
19.0 (SPSS Inc, Chicago, IL, USA). P values < 0.05 were
considered significant.
Results
FABP expression on transcript and protein levels in cell
lines
The general characteristic of all urological carcinoma
cell lines is the expression of E-and IL-FABP both on
mRNA and protein level (Figure 2A-C), while the
expressions differed between the cell lines. In addition,
in all cell lines studied neither the I-FABP protein nor
the I-FABP mRNA was detectable.
Renal cell carcinoma cell lines
The cell line HK-2 derived from normal renal tissue
only expressed mRNAs of E-FABP and IL-FABP. Its
mRNA expression pattern differed in comparison to the
five carcinoma cell lines 786-0, A 704, ACHN, Caki-1
and Caki-2, which showed additional FABPs. The 786-0
and Caki-1 cells expressed L-FABP, ACHN cells
expressed H-FABP and A 704 and Caki-2 cells
expressed B-FABP.
The protein expression was not always congruent with
the mRNA expression and the levels of E- and IL-FABP
in these cells were different in the cell lines. In 786-0, A
498 and Caki-2 cells, the E-FABP protein expression
was very high (Figure 3A). Caki-2 cells were charac-
terised also by a high IL-FABP level. All the other
mRNAs except B-FABP in Caki-2 cells (Figure 2A) were
not transcribed to the corresponding protein that was
not detectable at all.
Urinary bladder carcinoma cell lines
E- and IL-FABP were ubiquitously detectable as mRNA
and protein in all bladder cell lines (Figure 2B). The
protein expression level was increased in the carcinoma
lines in comparison to normal bladder cell line HCV-29
(Figure 3B). The carcinoma cell lines were characterised
by the two additional H- and A-FABP mRNAs. The
mRNA and protein expression was not always congru-
ent. The HT-1376, J-82 and SCaBER cells expressed A-
FABP mRNA, but the protein was not detectable. The
situation for the H-FABP mRNA was similar. The high-
est A-FABP mRNA expression was observed in RT-4
and RT-112 cells and here the protein was also detect-
able (Figure 3B).
Prostate carcinoma cell lines
E-FABP was found to be the main FABP in prostate car-
cinoma cell lines (Figure 2C), while the LNCaP cell lines
showed the lowest mRNA expression and the protein
expression was lacking (Figure 3C). The expression of
IL-FABP mRNA was lower compared to the E-FABP
mRNA. The protein detection of IL-FABP was positive
in all cell lines, but distinct intensity differences were
observed. In DU-145 and 22 RV-1 cells, the protein con-
tent was lower than in the other cell lines (Figure 3C).
The benign prostate hyperplasia cell line (BPH-1) was
characterised by the two additional mRNAs of H-FABP
and A-FABP. Two cell lines derived from metastasis,
DU-145 and LNCaP, lost of these two mRNAs (H-FABP
and A-FABP). The 22 RV-1 cells, derived from a pri-
mary prostate carcinoma, were marked by the loss of A-
FABP mRNA and appearance of B-FABP mRNA and
the corresponding protein. Protein detection of H- and
A-FABP was not possible in all cell lines, so that
Table 5 Antibodies for Western Blot detection
Protein Species Supplier Concentration
L-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 1 μg/ml
I-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 2 μg/ml
H-FABP Mouse IgG1 monoclonal
Clone 66E2
Hycult biotechnology b.v., Uden, Netherlands 1 μg/ml
A-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 0.2 μg/ml
E-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 0.1 μg/ml
IL-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 1 μg/ml
B-FABP Rabbit IgG polyclonal Hycult biotechnology b.v., Uden, Netherlands 1 μg/ml
b-actin Mouse IgG2 monoclonal
Clone AC-74
Sigma-Aldrich Chemie GmbH, Munich, Germany 2.1 μg/ml
anti-rabbit IgG/HRP* Goat polyclonal DakoCytomation, Glostrup, Denmark 0.12 μg/ml
anti-mouse IgG/HRP* Rabbit polyclonal DakoCytomation, Glostrup, Denmark 0.53 μg/ml
* HRP - Horseradish peroxidase
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appeared there, too.
IL-FABP mRNA expression in RCC tissue
The expression of IL-FABP in normal and tumour tis-
sues were normalised against the geometric mean
expression of the two reference genes PPIA and TBP.
The increase of IL-FABP in the tumour tissues was cal-
culated as relation of normalised concentration in
tumour tissue to normalised concentration in normal
tissue and further on mentioned as ratio. The IL-FABP
mRNA expression was 137-times higher (median) in
RCC than in the normal tissue (p < 0.0001; Figure 4).
The IL-FABP ratio was not correlated to the tumour
grade and stage (rs = -0.143, p = 0.343; rs = -0.181, p =
0.228). Samples from patients without metastasis at the
time of radical nephrectomy (27 cases) displayed a 139-
fold (median) over-expression (Figure 4), while samples
from nephrectomised patients with metastases showed
116-fold (median) over-expression (Figure 4). This dif-
ference was not significant (p = 0.219).
IL-FABP expression and patient survival time
The tumour cohort studied was representative because
the conventional prognostic parameters (tumour stage,
tumour grade and metastasis) reached significance for
survival in Kaplan-Meier analysis (Figure 5). Patients
with high-stage, high-grade tumours and with
Figure 2 FABP subtype mRNA expression in the various
carcinoma cell lines. (A) Renal cell carcinoma cell lines; (B) Urinary
bladder carcinoma cell lines; (C) Prostate carcinoma cell lines. P
labelled the immunoblot detection of FABP and P* marked a very
strong immunoblot detection of FABP.
Figure 3 Western blot detection of FABP subtypes in various
carcinoma cell lines. Exemplary protein detection in (A) renal
carcinoma cells in (B) urinary bladder carcinoma cells and in (C)
prostate carcinoma cells.
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Taking all patients together, the IL-FABP ratio in the
tumour tissue was not associated with the survival
time (log rank test, p = 0.194). However, differences
were found when the two subgroups of patients with
and without metastasis at the date of radical nephrect-
omy were separately analysed. In patients without
metastasis, no association was found between the IL-
FABP ratio and the survival time (log-rank test, p =
0.755). In contrast, in the group of patients with dis-
tant metastases (M1; n = 19), an increased ratio of IL-
FABP in the malignant compared with the non-malig-
nant tissue sample was significantly associated with a
longer survival time (log-rank test, p = 0.004; Figure
5C). Using the multivariable Cox regression analysis
with the variables pT stage, grade, metastasis and the
mentioned IL-FABP ratio, IL-FABP arose as indepen-
dent variable (log-rank test, p = 0.029). This result was
internally validated with a bootstrap analysis with 5000
bootstrap replicates and the 95% percentile approach.
The independence of the variable IL-FABP ratio was
confirmed (log-rank test, p = 0.026).
Discussion
Approximately one quarter of all newly diagnosed can-
cer patients have urological tumours [11]. Thus, the
purpose to improve early diagnosis and to introduce
new reliable therapies for these cancer patients is a
main objective of urological research. It is based on the
search for characteristic tissue markers that can be used
not only as diagnostic and/or prognostic biomarkers but
also as targets for new treatment strategies. In this
respect, the altered expression of FABPs in solid
tumours and especially in urological tumours is of great
interest as briefly discussed in the section Background
(Table 1). The observation of altered expression is to be
verified under experimental conditions and it is neces-
sary to work with well described permanent cell lines
relating to the FABP expression. To the best of our
knowledge we present in this study the first systematic
investigation concerning the expression of most FABPs
in urological cell lines.
Our data show three essential features: (a) the expres-
sion of E- and IL-FABP and the lack of expression of I-
FABP on mRNA and protein levels in all urological cell
lines (Figure 2A-C), (b) the inconsistent congruence
between the mRNA expression and protein expression
differing both between the various FABPs and the cell
lines as described in detail in the section Results and (c)
the different patterns of FABPs not only between but
also within the organ-specific cell lines.
Discrepancies between RNA and protein could be
explained by different analytical sensitivities of the
methods, in case of RT-PCR and Western blot techni-
que, and more probably, by biological reasons. As exten-
sive cellular machinery is involved in the process of
translation, possible differences between RNA and pro-
tein expression can be caused by posttranscriptional reg-
ulatory mechanisms. These processes are still poorly
understood. One possibility is that small non-coding
RNAs might influence the translation.
In addition to the general expression of E- and IL-
FABP in all cell lines, five out of the eight investigated
renal cell carcinoma cell lines showed expressions of L-,
H- and B-FABP mRNA. Only the Caki-2 cells repre-
sented the situation in renal cell carcinoma tissue, parti-
cularly the decreased or absent expression of L- and H-
FABP and the up-regulation of B-FABP mRNA. Protein
of B-FABP was exclusively detectable in the Caki-2 cells.
It was known from earlier studies [4,5] that renal
tumour tissue showed reduced expression levels of L-
FABP and H-FABP and increased B-FABP compared to
normal renal tissues.
The results of IL-FABP expression and our previous
observations regarding the clinical significance of B- and
L-FABPs in renal cell carcinoma [4] prompted us to
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Figure 4 IL-FABP ratio in a cohort of patients with renal cell
carcinoma. The IL-FABP ratio was calculated as relation of
normalised IL-FABP mRNA concentration in tumour tissue to
normalised concentration in normal tissue. Expression data were
normalised against the geometric means of the two reference
genes PPIA and TBP. The median of IL-FABP ratio was calculated for
all patients, for Patients without metastasis (M0) and for patients
with metastasis (M1): Statistical differences were calculated by the
Mann Whitney test.
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Page 7 of 10Figure 5 Kaplan-Meier survival curves for IL-FABP mRNA expression in matched RCC tissue samples.( A )F u h r m a ng r a d e s1a n d2
compared to 3 and 4, (B) Tumour stage pT1 and pT2 (tumour is limited to the kidney) compared to pT3 and pT4 (tumour extends over the
organ), (C) Patients without metastasis (M0) compared to those with metastasis (M1), (D) IL-FABP ratio above and below the median was
compared for all cases, (E) IL-FABP ratio above and below the median was compared in the group of patients without metastasis (M0), (F) IL-
FABP ratio above and below the median was compared in the group of patients with metastasis (M1).
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nant and non-malignant specimens from kidney after
radical nephrectomy. IL-FABP mRNA was over-
expressed in the tumour tissue and no statistical differ-
ences were observed between samples from patients
with and without metastases at the date of surgery.
However, it was remarkable that patients with metastasis
and an increased IL-FABP mRNA ratio showed a longer
survival time. The IL-FABP ratio was identified as an
independent indicator for survival outcome. Along with
the retrospective nature of this study, the low number
of patients was a limitation of this investigation. How-
ever, the internal validation using a bootstrap approach
proved this result despite the low number of patients
investigated. Therefore, we consider this as preliminary
result that would be worth to be confirmed in further
studies. Patients with high grade tumours and metastasis
have a poor prognosis. In this group, a high IL-FABP
expression might be an advantage because the transport
of fatty acids could be enhanced. It is a speculation that
cells incorporate a large amount of long-chain polyunsa-
turated fatty acids and so the level of antioxidants could
be increased in the cells. This could be a protection
against elevated ROS level in cancer cells.
In summary, this and the former study showed that
the renal cell carcinoma tissue was characterised by
decreased L- and H-FABPs and increased B- and IL-
FABPs. The changes of these four FABP types indicate
fundamental alterations in the fatty acid metabolism in
the RCC carcinogenesis. Most of the investigated renal
carcinoma cell lines only partly reflected these changes
in tumour tissue.
In bladder cancer cell lines, we found in addition to
the general expression of E- and IL-FABP the expres-
sion of A-FABP in six examined cell lines, while H-
FABP was present only in three cell lines (HT-1376, J-
82, SCaBER). A high expression of A-FABP mRNA
and protein was observed in the well-differentiated
RT-4 and RT-112 cells, while the other cell lines,
which had been derived from less-differentiated, high-
grade bladder tumours such as HT-1376 cells showed
lower A-FABP mRNA expression. This result corre-
sponds to data of Ohlsson et al. [3] and Boiteux et al.
[12] who described the loss of A-FABP as marker for
bladder cancer progression. On the other hand, the E-
FABP mRNA expression in the HT-1376 cells, derived
from a poorly differentiated G3 tumour [13], was
higher than in the well-differentiated RT-112 cells,
whereas Ostergaard et al. [14] reported a decreased
expression of E-FABP in less-differentiated tumours.
Thus, this result also supports the conclusion that the
expression in the cells does not always reflect the
s i t u a t i o ni nt u m o u r s .
The expression pattern of various FABP types in pros-
tate cancer cell lines was previously described by Das et
al. [6]. The authors observed a strong reduction of A-,
E- and H-FABP in the cancer cell lines LNCaP, DU-145,
and PC-3 compared to cells from normal primary cell
cultures. The present work proved this result for A- and
E-FABP in comparison to the BPH-1 cells derived from
benign prostate hyperplasia. We observed in androgen-
s e n s i t i v eL N C a Pc e l l sam o r et h a n1 5 0 0 - f o l dl o w e r
expression of E-FABP than in androgen-insensitive
BPH-1. The expression of B-FABP mRNA and protein
was observed only in the 22 RV-1 cells derived from a
primary tumour. Das et al. [6] observed B-FABP in
LNCaP cells and in prostate cancer tissues of well-differ-
entiated tumours and suggested B-FABP as stage-speci-
fic marker in prostate cancer. L-and I-FABP were not
detected in the present study at all. LNCaP cells were
characterised by IL-FABP and a low expression of E-
FABP mRNA.
Conclusions
Our study is the first report about the mRNA and pro-
tein expression of various FABP types in frequently used
cell lines from prostate, bladder, and kidney cancers.
Regarding to carcinoma cell lines, distinct differences of
FABP expression patterns were observed between the
cells derived from the three cancer types but also
between the organ-specific cell lines. In addition, the
FABP patterns in the cell lines do not reflect the real
situation in the tumours. It was suggested that in nor-
mal tissues a balance exists between different FABP
types and that this balance is destroyed in cancerogen-
esis causing a new composition of FABP types [6]. To
study this effect in more detail, the knowledge on the
FABP expression as given in this study might be helpful
in selecting an appropriate cell line for experimental
work.
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